Search alternatives:
significant cause » significant change (Expand Search), significant changes (Expand Search), significant gap (Expand Search)
marked decrease » marked increase (Expand Search)
cause decrease » caused decreased (Expand Search), use decreased (Expand Search), causes increased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
significant cause » significant change (Expand Search), significant changes (Expand Search), significant gap (Expand Search)
marked decrease » marked increase (Expand Search)
cause decrease » caused decreased (Expand Search), use decreased (Expand Search), causes increased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
1
-
2
-
3
-
4
Mechlorethamine gel causes epithelium thinning, epithelium-stroma separation, and decreased total stroma cell count.
Published 2025“…<p>A) Epithelium thickness decreased, and B) the percentage of epithelium-stroma separation increased after NM exposure. …”
-
5
Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i>
Published 2025“…(B, C) Summarized bar graph showed EVO significantly decreased calcium deposition and calcium content in CER treated P<sub>i</sub>-induced VSMCs. …”
-
6
Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index.
Published 2025“…All groups were compared by Kruskal Wallis test with <i>post hoc</i> test after Dunn with Bonferroni adjustment showing significant decreased Ki-67 labeling index of <i>Cina1</i> compared to <i>Cina2</i> (p = 0.006) and the untreated CKD groups (p = 0.0001 and p = 0.0002, respectively). …”
-
7
Table 1_The impact of decreased prognostic nutritional index on the prognosis of patients with pneumonia treated with glucocorticoids: a multicenter retrospective cohort study.docx
Published 2025“…</p>Conclusion<p>Among pneumonia patients receiving glucocorticoid therapy, a decreased PNI was associated with an increased risk of 30-day and 90-day mortality, particularly in those with a PNI < 43.…”
-
8
Table 2_The impact of decreased prognostic nutritional index on the prognosis of patients with pneumonia treated with glucocorticoids: a multicenter retrospective cohort study.docx
Published 2025“…</p>Conclusion<p>Among pneumonia patients receiving glucocorticoid therapy, a decreased PNI was associated with an increased risk of 30-day and 90-day mortality, particularly in those with a PNI < 43.…”
-
9
Table 3_The impact of decreased prognostic nutritional index on the prognosis of patients with pneumonia treated with glucocorticoids: a multicenter retrospective cohort study.docx
Published 2025“…</p>Conclusion<p>Among pneumonia patients receiving glucocorticoid therapy, a decreased PNI was associated with an increased risk of 30-day and 90-day mortality, particularly in those with a PNI < 43.…”
-
10
Table 5_The impact of decreased prognostic nutritional index on the prognosis of patients with pneumonia treated with glucocorticoids: a multicenter retrospective cohort study.docx
Published 2025“…</p>Conclusion<p>Among pneumonia patients receiving glucocorticoid therapy, a decreased PNI was associated with an increased risk of 30-day and 90-day mortality, particularly in those with a PNI < 43.…”
-
11
Table 4_The impact of decreased prognostic nutritional index on the prognosis of patients with pneumonia treated with glucocorticoids: a multicenter retrospective cohort study.docx
Published 2025“…</p>Conclusion<p>Among pneumonia patients receiving glucocorticoid therapy, a decreased PNI was associated with an increased risk of 30-day and 90-day mortality, particularly in those with a PNI < 43.…”
-
12
Image 1_The impact of decreased prognostic nutritional index on the prognosis of patients with pneumonia treated with glucocorticoids: a multicenter retrospective cohort study.tif
Published 2025“…</p>Conclusion<p>Among pneumonia patients receiving glucocorticoid therapy, a decreased PNI was associated with an increased risk of 30-day and 90-day mortality, particularly in those with a PNI < 43.…”
-
13
Evogliptin attenuates the pyroptotic cell death of VSMCs during CER treatment by decreasing the pyroptotic-associated genes and GSDM-D cleavage efficiency <i>in-vitro.</i>
Published 2025“…<p>(A) Bar graph showed EVO significantly decreased Lactate dehydrogenase (LDH) release in CER treated P<sub>i</sub>‐induced VSMCs. …”
-
14
-
15
-
16
-
17
-
18
-
19
The table shows the significant and non-significant altered group with different parameters.
Published 2025Subjects: -
20